No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study.

ABSTRACT: This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection.

Introduction

Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women.

Methods

Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Tu

SUBMITTER: Atmaca A 

PROVIDER: S-EPMC8369875 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature